NO20083968L - Anvendelse av A2B-adenosinreseptorantagonister til a forebygge og behandle hepatisk sykdom - Google Patents

Anvendelse av A2B-adenosinreseptorantagonister til a forebygge og behandle hepatisk sykdom

Info

Publication number
NO20083968L
NO20083968L NO20083968A NO20083968A NO20083968L NO 20083968 L NO20083968 L NO 20083968L NO 20083968 A NO20083968 A NO 20083968A NO 20083968 A NO20083968 A NO 20083968A NO 20083968 L NO20083968 L NO 20083968L
Authority
NO
Norway
Prior art keywords
prevent
receptor antagonists
adenosine receptor
hepatic disease
treat hepatic
Prior art date
Application number
NO20083968A
Other languages
English (en)
Norwegian (no)
Inventor
Dewan Zeng
Luiz Belardinelli
Hongyan Zhong
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of NO20083968L publication Critical patent/NO20083968L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20083968A 2006-03-17 2008-09-17 Anvendelse av A2B-adenosinreseptorantagonister til a forebygge og behandle hepatisk sykdom NO20083968L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78357506P 2006-03-17 2006-03-17
PCT/US2007/064182 WO2007109547A2 (en) 2006-03-17 2007-03-16 Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
NO20083968L true NO20083968L (no) 2008-12-15

Family

ID=38514256

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083968A NO20083968L (no) 2006-03-17 2008-09-17 Anvendelse av A2B-adenosinreseptorantagonister til a forebygge og behandle hepatisk sykdom

Country Status (14)

Country Link
US (4) US7795268B2 (https=)
EP (1) EP1996201A2 (https=)
JP (2) JP5250848B2 (https=)
KR (1) KR101428113B1 (https=)
CN (1) CN101405003B (https=)
AU (1) AU2007227021B2 (https=)
CA (2) CA2646333C (https=)
IL (1) IL194158A0 (https=)
MX (1) MX2008011828A (https=)
NO (1) NO20083968L (https=)
NZ (1) NZ571324A (https=)
RU (1) RU2457842C2 (https=)
WO (1) WO2007109547A2 (https=)
ZA (1) ZA200807894B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080194593A1 (en) * 2001-11-09 2008-08-14 Rao Kalla A2b adenosine receptor antagonists
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
ES2557310T3 (es) * 2003-08-25 2016-01-25 Dogwood Pharmaceuticals, Inc. 8-heteroaril xantinas substituidas
EP1799221A1 (en) 2004-10-15 2007-06-27 Cv Therapeutics, Inc. Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists
US7598379B2 (en) 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
US7579348B2 (en) * 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
EP1891070A1 (en) * 2005-06-16 2008-02-27 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
AU2007227021B2 (en) 2006-03-17 2012-12-20 Gilead Sciences, Inc. Method of preventing and treating hepatic disease using A2B adenosine receptor antagonists
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
WO2008000743A2 (en) * 2006-06-27 2008-01-03 Biovitrum Ab (Publ) Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
US20090208550A1 (en) * 2007-10-26 2009-08-20 Cronstein Bruce N Methods and compositions for treating hepatic diseases
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
EP2268641B1 (en) * 2008-03-26 2014-09-03 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist
JP5765239B2 (ja) 2009-03-13 2015-08-19 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物
JP5843778B2 (ja) 2009-11-09 2016-01-13 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物、その調製およびその使用
CN103261200B (zh) 2010-09-13 2016-03-30 阿迪维纳斯疗法有限公司 作为a2b腺苷受体拮抗剂的前药的嘌呤化合物、它们的制备方法及医药用途
US20140142113A1 (en) * 2012-11-09 2014-05-22 Michael W. Burnet Method of treating inflammatory diseases using adenosine 2b receptor antagonists
US10583102B2 (en) 2014-10-06 2020-03-10 The Johns Hopkins University Targeting liver nuclear receptors as a treatment for wilson disease
WO2016129760A1 (ko) * 2015-02-13 2016-08-18 한국과학기술원 Tnp(n2-(m-trifluorobenzyl), n6-(p-nitrobenzyl)purine)를 유효성분으로 함유하는 아세트아미노펜 유래 간 독성 예방 및 치료용 조성물
KR101666605B1 (ko) 2015-02-13 2016-10-18 한국과학기술원 TNP(N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine)를 유효성분으로 함유하는 아세트아미노펜 유래 간 독성 예방 및 치료용 조성물
EP3368064B1 (en) 2015-10-29 2021-05-19 CLS Therapeutics Limited Use of dnase to improve safety and efficacy of anti-cancer chemotherapy
WO2017139455A1 (en) 2016-02-10 2017-08-17 Wake Forest University Health Sciences Model system of liver fibrosis and method of making and using the same
KR101709307B1 (ko) * 2016-10-31 2017-02-23 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 비알콜성 지방간염, 간섬유증 및 간경변증 예방 및 치료용 약학적 조성물
US11220492B2 (en) 2017-05-17 2022-01-11 Arcus Biosciences, Inc. Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders
CN111629728A (zh) * 2017-08-31 2020-09-04 科尔沃斯制药股份有限公司 用于调节腺苷a2b受体和腺苷a2a受体的化合物和方法
ES2975753T3 (es) 2018-03-05 2024-07-12 Teon Therapeutics Inc Antagonistas del receptor de adenosina y usos de los mismos
GB201804922D0 (en) 2018-03-27 2018-05-09 Ucl Business Plc Traatment
US12064433B2 (en) 2018-07-27 2024-08-20 Arcus Biosciences, Inc. Pyridone A2R antagonists
CN111686239B (zh) * 2019-03-11 2021-12-24 中国科学院微生物研究所 抗真菌化合物的应用
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0028383D0 (en) * 2000-11-21 2001-01-03 Novartis Ag Organic compounds
DK1444233T3 (da) * 2001-11-09 2011-10-17 Gilead Palo Alto Inc A2B-adenosinreceptorantagonister
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
ES2208063B1 (es) 2002-04-01 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida.
IL160133A0 (en) * 2002-05-30 2004-06-20 King Pharmaceuticals Res & Dev Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
WO2004086052A2 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a2b (adora2b)
GB0401336D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
EP1891070A1 (en) 2005-06-16 2008-02-27 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
AU2007227021B2 (en) * 2006-03-17 2012-12-20 Gilead Sciences, Inc. Method of preventing and treating hepatic disease using A2B adenosine receptor antagonists

Also Published As

Publication number Publication date
WO2007109547A2 (en) 2007-09-27
KR20080107416A (ko) 2008-12-10
US8188099B2 (en) 2012-05-29
RU2457842C2 (ru) 2012-08-10
US20070219221A1 (en) 2007-09-20
CA2646333C (en) 2014-06-17
US20110184002A1 (en) 2011-07-28
AU2007227021A1 (en) 2007-09-27
NZ571324A (en) 2011-07-29
JP2013049719A (ja) 2013-03-14
US20140243358A1 (en) 2014-08-28
EP1996201A2 (en) 2008-12-03
MX2008011828A (es) 2008-09-29
WO2007109547A3 (en) 2007-11-29
RU2008137279A (ru) 2010-03-27
IL194158A0 (en) 2009-08-03
CN101405003A (zh) 2009-04-08
JP2009530413A (ja) 2009-08-27
US8609671B2 (en) 2013-12-17
KR101428113B1 (ko) 2014-08-07
CN101405003B (zh) 2011-05-11
US20120220608A1 (en) 2012-08-30
JP5250848B2 (ja) 2013-07-31
CA2849661A1 (en) 2007-09-27
CA2646333A1 (en) 2007-09-27
US7795268B2 (en) 2010-09-14
ZA200807894B (en) 2009-05-27
AU2007227021B2 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
NO20083968L (no) Anvendelse av A2B-adenosinreseptorantagonister til a forebygge og behandle hepatisk sykdom
WO2010034670A3 (en) Host cell kinases as targets for antiviral therapies against hcv infection
BRPI0622054B8 (pt) composto e composição farmacêutica
NO20090469L (no) Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav
MX2020005345A (es) Un método para inhibir o reducir una infección viral por coronavirus.
NO20084747L (no) Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser
MY141025A (en) Dose forms
ECSP066791A (es) Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
BRPI0822335A2 (pt) inibidores do vírus da hepatite c
NO20090453L (no) Hepatitt C Virusinhibitorer
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
EA201490654A1 (ru) Новые ингибиторы вирусной репликации
WO2014089296A3 (en) Functionalized benzamide derivatives as antiviral agents against hbv infection
WO2008076392A3 (en) Compounds useful as protein kinase inhibitors
WO2007143607A3 (en) Method of treating atrophic vaginitis
MY145349A (en) Benzofuro- and benzothienopyrimidine modulators of the histamine h4 receptor
NO20084411L (no) Tetrahydro-pyrimidoazepiner som modulatorer av TRPVI
DK2012764T3 (da) Farmaceutisk kombination omfattende 3-(3-dimethylamino-1-ethyl-2methyl-propyl)-phenol og paracetamol
BRPI0922789A2 (pt) peptídeo de ligação de albumina intermediador para reconhecimento de doença
MX2013000242A (es) Tratamiento de enfermedades relacionadas con el virus de hepatitis c que usa hidroxicloroquina o una combinacion de hidroxicloroquina y un agente antiviral.
ATE528309T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
BR112014014805A2 (pt) processos para tratamento e prevenção de constipação induzida por opióide que utilizam composições orais de metilnaltrexona
WO2008033754A3 (en) Xanthine derivatives in methods and compositions for the treatment of vascular depression
WO2006133194A3 (en) Methods for treating viral infection with oral or injectible drug solution
WO2008121461A3 (en) Vaccine for activating helper function of cd8+ tcells

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application